ICON Issues Financial Guidance for Full Year 2020
Full Year 2020 Revenue guidance in the range of $2,972 - $3,092 million, representing growth of 5.8 – 10.0%.
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020
ICON’s financial guidance for the year ended December 31, 2020 will be released by press release on Tuesday, January 14, 2020
ICON Wins Best Contract Research Organisation – Full-Service Providers at the 15th Annual Scrip Awards 2019
ICON awarded for capabilities and innovations in successful drug development and patient recruitment
ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference
Wednesday, November 27, 2019.
ICON plc to Present at Jefferies 2019 London Healthcare Conference
Thursday, November 21, 2019.
ICON’s Acquisition of Symphony Clinical Research
The acquisition further enhances ICON’s patient, site and data strategy and complements ICON’s existing PMG Research and MeDiNova Research site networks in the US and EMEA.
ICON Reports Third Quarter 2019 Results
Quarter 3 reported revenue of $710.4 million. This represents strong year on year growth of 8.5% or 9.5% on a constant currency basis.
ICON plc to Present at Baird’s 2019 Global Healthcare Conference
Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present
ICON Reports Second Quarter 2019 Results
Net business wins (including pass-through) in the quarter of $901 million; a book to bill of 1.30.
ICON announces the appointment of Ms. Julie O’Neill to Board of Directors
And confirms the retirement of Professor Dermot Kelleher and Mr. Declan McKeon